Physician profile

Harold Cesar

Foot & Ankle Surgery · Jacksonville, FL

NPI 1891010344

$514.99

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$104.12

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Horizon Therapeutics Plc $120.47 2019
Organogenesis INC. $80.07 2020-2022
Reddress USA, INC. $79.69 2024
Smith+Nephew, INC. $75.14 2019-2023 Bone Anchors With Arthroscopic Delivery System
Wright Medical Technology, INC. $39.57 2019-2020
Stryker Corporation $34.36 2021
Djo, LLC $26.14 2019
Pacira Pharmaceuticals Incorporated $24.55 2019
Masimo Corporation $19.57 2021
Zimmer Biomet Holdings, INC. $15.43 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Harold Cesar

$514.99

in general payments reported 2019-2025

Years
2019-2024
Top company
Horizon Therapeutics Plc

https://glasscript.com/doctor/86073/harold-cesar

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.